| Proton-pump inhibitors are the treatment of choice in acid-related disease. | |
| | |
MedLine Citation:
|
PMID: 8930574 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INCREASING INTRAGASTRIC PH: Effective treatment of acid-related disease requires an increase in intragastric pH. The two principal pharmacological methods of attaining this goal are (1) using histamine (H2)-receptor antagonists to block H2-receptors on the parietal cell and (2) using proton-pump inhibitors to stop acid production acid at its source. H2-RECEPTOR ANTAGONISTS: H2-receptor antagonists bind loosely and non-covalently to receptors on the parietal cell. They represented a great advance when they first appeared, bringing relief to many patients and improving the standard of care, with fewer operations and hospitalizations and a generally improved quality of life. However, many patients do not respond to these drugs, either because of the nature of the disease or because of resistance to the agent. PROTON-PUMP INHIBITORS: Proton-pump inhibitors represent an advance in the therapy of acid-related disease because they inhibit all acid production, no matter what the source of the stimulus, by binding covalently to the proton pump. Compared with H2-receptor antagonists, the effect of proton-pump inhibition is longer-lasting, faster-acting, and more effective, curing 99% of patients resistant to H2-receptor antagonist therapy. These properties make proton-pump inhibitors the treatment of choice for acid-related diseases. |
| | |
Authors:
|
G Brunner |
Related Documents
:
|
16354514 - Role of gastric acid in stomal ulcer after gastric bypass. 1636704 - Duodenal intramural nerves in control of pyloric motility and gastric emptying. 10761684 - Comparison of five antisecretory agents acting via gastric h+/k+-atpase. 879914 - Inhibitory effect of fumaric acid and dicarboxylic acids on gastric ulceration in rats. 1128174 - Effect of dietary safflower oil upon lipogenesis in neonatal lamb. 16354514 - Role of gastric acid in stomal ulcer after gastric bypass. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 8 Suppl 1 ISSN: 0954-691X ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 1996 Oct |
Date Detail:
|
Created Date: 1997-01-21 Completed Date: 1997-01-21 Revised Date: 2009-10-16 |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: S9-13 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University Medical School, Hannover, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Ulcer Agents
/
pharmacology,
therapeutic use* Enzyme Inhibitors / pharmacology, therapeutic use* H(+)-K(+)-Exchanging ATPase / antagonists & inhibitors* Histamine H2 Antagonists / pharmacology, therapeutic use* Humans Peptic Ulcer / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Ulcer Agents; 0/Enzyme Inhibitors; 0/Histamine H2 Antagonists; EC 3.6.1.10/H(+)-K(+)-Exchanging ATPase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The changing role of H2-receptor antagonists in acid-related diseases.
Next Document: Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity.